Synmosa Biopharma (Taiwan) Insiders
| 4114 Stock | TWD 34.80 0.10 0.29% |
Synmosa Biopharma employs about 16 people. The company is managed by 7 executives with a total tenure of roughly 27 years, averaging almost 3.0 years of service per executive, having 2.29 employees per reported executive. Recap of Synmosa Biopharma's management performance can provide insight into the venture performance.
| ChihHui Lin Insider GM, Chairman |
| Zen Young Insider Marketing HP |
Synmosa |
Synmosa Biopharma Management Team Effectiveness
The company has return on total asset (ROA) of 0.0223 % which means that it generated a profit of $0.0223 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0894 %, meaning that it generated $0.0894 on every $100 dollars invested by stockholders. Synmosa Biopharma's management efficiency ratios could be used to measure how well Synmosa Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Synmosa Biopharma Workforce Comparison
Synmosa Biopharma is rated fourth in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is presently estimated at about 100.0. Synmosa Biopharma retains roughly 16.0 in number of employees claiming about 16% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 0.18 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09. Synmosa Biopharma Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Synmosa Biopharma Price Series Summation is a cross summation of Synmosa Biopharma price series and its benchmark/peer.
Synmosa Biopharma Notable Stakeholders
A Synmosa Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Synmosa Biopharma often face trade-offs trying to please all of them. Synmosa Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Synmosa Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shengren Yang | Director | Profile | |
| ChihHui Lin | GM, Chairman | Profile | |
| Zen Young | Marketing HP | Profile | |
| Hongqin Bai | Sr Officer | Profile | |
| Banson Lin | Sr Distributors | Profile | |
| JiaXin Zhang | VP | Profile | |
| HungChin Pai | VP Officer | Profile |
About Synmosa Biopharma Management Performance
The success or failure of an entity such as Synmosa Biopharma often depends on how effective the management is. Synmosa Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Synmosa management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Synmosa management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
Please note, the imprecision that can be found in Synmosa Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Synmosa Biopharma. Check Synmosa Biopharma's Beneish M Score to see the likelihood of Synmosa Biopharma's management manipulating its earnings.
Synmosa Biopharma Workforce Analysis
Traditionally, organizations such as Synmosa Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Synmosa Biopharma within its industry.Synmosa Biopharma Manpower Efficiency
Return on Synmosa Biopharma Manpower
| Revenue Per Employee | 202.2M | |
| Revenue Per Executive | 462.1M | |
| Net Income Per Employee | 19M | |
| Net Income Per Executive | 43.4M |
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.